title: Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
abstract: In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced binge eating days (primary endpoint) in adults with binge eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global binge eating severity and obsessive-compulsive and impulsive features of BED in addition to binge eating days.
authors.affiliation: University of Cincinnati College of Medicine, Cincinnati, OH, USA.|Lindner Center of HOPE, Mason, OH, USA.
authors.forename: Susan L
authors.initials: SL
authors.lastname: McElroy
authors.affiliation: Neuropsychiatric Research Institute, Fargo, ND, USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Mitchell
authors.affiliation: Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Denise
authors.initials: D
authors.lastname: Wilfley
authors.affiliation: Shire, Wayne, PA, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Gasior
authors.affiliation: Shire, Wayne, PA, USA.
authors.forename: M Celeste
authors.initials: MC
authors.lastname: Ferreira-Cornwell
authors.affiliation: Shire, Wayne, PA, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: McKay
authors.affiliation: CSL Behring, King of Prussia, PA, USA (previously employed at Shire).
authors.forename: Jiannong
authors.initials: J
authors.lastname: Wang
authors.affiliation: Shire, Wayne, PA, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Whitaker
authors.affiliation: McLean Hospital/Harvard Medical School, Belmont, MA, USA.
authors.forename: James I
authors.initials: JI
authors.lastname: Hudson
mesh_terms: D000293:Adolescent; D000328:Adult; D056912:Binge-Eating Disorder / Q000188:drug therapy*; D002032:Bulimia / Q000523:psychology; D003192:Compulsive Behavior; D004311:Double-Blind Method; D005247:Feeding Behavior / Q000187:drug effects*; D005260:Female; D006801:Humans; D007175:Impulsive Behavior / Q000187:drug effects; D000069478:Lisdexamfetamine Dimesylate / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009770:Obsessive Behavior; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000069478:Lisdexamfetamine Dimesylate
keywords: binge eating disorder; impulsivity; lisdexamfetamine dimesylate; obsessive-compulsive